Status: Not yet recruiting
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
The objective of this Phase II, open-label, multicenter, non-randomised controlled clinical trial is to guide precision treatment for patients with rare tumours based on Patient-Derived Organoids/Next-Generation Sequencing drug screening.
Participants needed: 200
Trial details
Phase: Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Peking University Shenzhen HospitalUpdated: Nov 18, 2024
Eligibility criteria
Male or female, the age at the time of signing the informed consent is no less t... [+12]
No patient lesions available for organoid model construction; [+25]